MEN'S ROGAINE SOLUTION

Nchi: Kanada

Lugha: Kiingereza

Chanzo: Health Canada

Viambatanisho vya kazi:

MINOXIDIL

Inapatikana kutoka:

JOHNSON & JOHNSON INC

ATC kanuni:

D11AX01

INN (Jina la Kimataifa):

MINOXIDIL, TOPICAL

Kipimo:

20MG

Dawa fomu:

SOLUTION

Tungo:

MINOXIDIL 20MG

Njia ya uendeshaji:

TOPICAL

Vitengo katika mfuko:

60ML

Dawa ya aina:

OTC

Eneo la matibabu:

MISC. SKIN AND MUCOUS MEMBRANE AGENTS

Bidhaa muhtasari:

Active ingredient group (AIG) number: 0114429001; AHFS:

Idhini hali ya:

APPROVED

Idhini ya tarehe:

2000-05-03

Tabia za bidhaa

_Product Monograph Master Template _
_ _
_Men’s ROGAINE® Minoxidil Topical Solution _
_Men’s ROGAINE® Foam 5% Minoxidil Foam _
_Women’s ROGAINE® Foam 5% Minoxidil Foam _
_ _
_Page 1 of 66_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
MEN’S ROGAINE®
Minoxidil Topical Solution
20 mg/mL (2% w/v)
Men’s ROGAINE® FOAM 5%
Minoxidil Foam 50 mg/g (5% w/w)
Women’s ROGAINE® FOAM 5%
Minoxidil Foam 50 mg/g (5%w/w)
Hair Regrowth Treatment
Johnson & Johnson Inc.
88 McNabb Street
Markham, ON
L3R 5L2
Date of Initial Authorization:
OCT 17, 2003
Date of Revision:
JAN 20, 2022
Submission Control Number: 251296
_Product Monograph Master Template _
_ _
_Men’s ROGAINE® Minoxidil Topical Solution _
_Men’s ROGAINE® Foam 5% Minoxidil Foam _
_Women’s ROGAINE® Foam 5% Minoxidil Foam _
_ _
_Page 2 of 66_
TABLE OF CONTENTS
TABLE OF CONTENTS
................................................................................................................2
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................................4
1
INDICATIONS
................................................................................................................4
1.1
Pediatrics
............................................................................................................4
1.2
Geriatrics.............................................................................................................4
2
CONTRAINDICATIONS
...................................................................................................4
4
DOSAGE AND
ADMINISTRATION...................................................................................5
4.1
Dosing Considerations
.........................................................................................5
4.2
Recommended Dose and Dosage
Adjustment.......................................................5
4.4
Administration.....................................................................................................6
4.5
Misse